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Background
Organic nitrates represent a class of very effective anti-
ischemic drugs used for the treatment of angina pectoris,
myocardial infarction and congestive heart failure [1]. A
limitation of their clinical use is the development of
nitrate tolerance. A remarkable exception is the long-act-
ing drug pentaerythrityl tetranitrate (PETN), which was
shown to cause no tolerance [2]. The mitochondrial iso-
form of aldehyde dehydrogenase (ALDH2) was shown to
be involved in bioactivation of nitroglycerin (GTN) [3]
and PETN [4]. The present work was carried out to study
the molecular mechanisms underlying the pharmacologi-
cal differences between GTN and PETN at the level of puri-
fied ALDH2.
Results
As quantified by liquid chromatography-mass spectros-
copy (LC-MS) ALDH2 metabolized 50 μM PETN to 14.84
± 4.05 nmol/min/mg pentaerythrityl trinitrate (PETriN)
in the absence and 62.38 ± 7.21 nmol/min/mg PETriN in
the presence of the reducing agent dithiothreitol. Co-incu-
bation of 2 μM [14C]GTN with ALDH2 and increasing
concentrations of PETN resulted in only small decreases
in 1,2-glyceroldinitrate formation as measured by radio
thin layer chromatography (control: 7.98 ± 0.20, 1 μM
PETN: 7.95 ± 0.20, 10 μM PETN: 7.41 ± 0.18, 100 μM
PETN: 6.66 ± 0.50 nmol/min/mg) indicating that PETN
does not compete with GTN metabolism. In the presence
of 25 μg of ALDH2 PETN activated soluble guanylate
cyclase (sGC) with an EC50 of 3.61 ± 0.35 μM and a max-
imum at 30 μM PETN (2.67 ± 0.12 μmol/min/mg). This
effect was enhanced by superoxide dismutase (SOD)
resulting in an EC50 of 0.64 ± 0.08 μM and maximal sGC
activation (18.44 ± 0.27 μmol/min/mg in the presence of
30 μM PETN). ALDH2 activity, measured as formation of
NADH from NAD+ in the presence of acetaldehyde, was
rapidly inactivated by GTN but not by PETN (1 mM each).
Conclusion
Low and high affinity pathways of PETN may explain the
apparent differences between PETN metabolism and bio-
activation, respectively. The reaction of PETN with
ALDH2 leads to activation of sGC with markedly higher
values in the presence of SOD suggesting formation of
superoxide as a co-product of PETN metabolism. The lack
of vascular tolerance to PETN may be due to significantly
lower rates of ALDH2 inactivation as compared to GTN.
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